6 34

Cited 0 times in

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

 Lillian M Smyth  ;  Sarina A Piha-Paul  ;  Helen H Won  ;  Alison M Schram  ;  Cristina Saura  ;  Sherene Loi  ;  Janice Lu  ;  Geoffrey I Shapiro  ;  Dejan Juric  ;  Ingrid A Mayer  ;  Carlos L Arteaga  ;  Macarena I de la Fuente  ;  Adam M Brufksy  ;  Iben Spanggaard  ;  Morten Mau-Sørensen  ;  Monica Arnedos  ;  Victor Moreno  ;  Valentina Boni  ;  Joohyuk Sohn  ;  Lee S Schwartzberg  ;  Xavier Gonzàlez-Farré  ;  Andrés Cervantes  ;  François-Clement Bidard  ;  Alexander N Gorelick  ;  Richard B Lanman  ;  Rebecca J Nagy  ;  Gary A Ulaner  ;  Sarat Chandarlapaty  ;  Komal Jhaveri  ;  Elena I Gavrila  ;  Catherine Zimel  ;  S Duygu Selcuklu  ;  Myra Melcer  ;  Aliaksandra Samoila  ;  Yanyan Cai  ;  Maurizio Scaltriti  ;  Grace Mann  ;  Feng Xu  ;  Lisa D Eli  ;  Melanie Dujka  ;  Alshad S Lalani  ;  Richard Bryce  ;  José Baselga  ;  Barry S Taylor  ;  David B Solit  ;  Funda Meric-Bernstam  ;  David M Hyman 
 CANCER DISCOVERY, Vol.10(2) : 198-213, 2020-02 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols / pharmacology ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / genetics ; Breast Neoplasms / pathology ; Breast Neoplasms, Male / drug therapy* ; Breast Neoplasms, Male / genetics ; Breast Neoplasms, Male / pathology ; Cell Line, Tumor ; DNA Mutational Analysis ; Drug Resistance, Neoplasm / drug effects ; Drug Resistance, Neoplasm / genetics ; Drug Synergism ; Estrogen Receptor Antagonists / pharmacology ; Estrogen Receptor Antagonists / therapeutic use ; Female ; Fulvestrant / pharmacology ; Fulvestrant / therapeutic use ; Humans ; Male ; Middle Aged ; Mutation ; Prospective Studies ; Protein Kinase Inhibitors / pharmacology ; Protein Kinase Inhibitors / therapeutic use ; Quinolines / pharmacology ; Quinolines / therapeutic use ; Receptor, ErbB-2 / antagonists & inhibitors* ; Receptor, ErbB-2 / genetics ; Receptor, ErbB-2 / metabolism ; Receptors, Estrogen / antagonists & inhibitors* ; Receptors, Estrogen / metabolism ; Signal Transduction / drug effects ; Signal Transduction / genetics ; Treatment Outcome
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. SIGNIFICANCE: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.
Files in This Item:
T9992020456.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.